title: Mechanism of azithromycin treatment on gingival overgrowth.
abstract: Azithromycin is effective for the remission of cyclosporine A-induced gingival overgrowth (CIGO) in persons who have undergone renal transplant. To explain its mechanism in alleviating the clinical symptoms of these individuals, we examined the effect of azithromycin on cell proliferation and collagen turnover modified by cyclosporin A in human gingival fibroblasts from healthy persons and from persons who had undergone renal transplant. Cyclosporin A-induced proliferation of renal transplant fibroblasts and normal fibroblasts was inhibited by azithromycin. Azithromycin elevated the reduced metalloproteinase (MMP)-1 and MMP-2 activities in cyclosporine A-treated renal transplant fibroblasts and normal fibroblasts. In cyclosporine A-treated renal transplant fibroblasts, azithromycin blocked the accumulation of total collagen in culture media and the increase in type I collagen mRNA level, but recovered the reduced MMP-2 mRNA level to the control. These results suggest that azithromycin may improve CIGO by blocking cyclosporine A-induced cell proliferation and collagen synthesis, and by activating MMP-2 in gingival fibroblasts of persons with cyclosporine A-induced gingival overgrowth.
authors.affiliation: Department of Oral Biology, Yonsei University College of Dentistry, 134 Shinchon-Dong, Seodaemoon-Ku, Seoul 120-752, South Korea.
authors.forename: J-Y
authors.initials: JY
authors.lastname: Kim
authors.forename: S-H
authors.initials: SH
authors.lastname: Park
authors.forename: K-S
authors.initials: KS
authors.lastname: Cho
authors.forename: H-J
authors.initials: HJ
authors.lastname: Kim
authors.forename: C-K
authors.initials: CK
authors.lastname: Lee
authors.forename: K-K
authors.initials: KK
authors.lastname: Park
authors.forename: S-H
authors.initials: SH
authors.lastname: Choi
authors.forename: W-Y
authors.initials: WY
authors.lastname: Chung
mesh_terms: D000328:Adult; D017963:Azithromycin / Q000494:pharmacology* / Q000627:therapeutic use*; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D020219:Chondrogenesis / Q000187:drug effects*; D024042:Collagen Type I / Q000096:biosynthesis; D016572:Cyclosporine / Q000009:adverse effects; D020536:Enzyme Activators / Q000494:pharmacology* / Q000627:therapeutic use*; D005260:Female; D005347:Fibroblasts / Q000187:drug effects / Q000201:enzymology; D019214:Gingival Overgrowth / Q000139:chemically induced / Q000188:drug therapy* / Q000201:enzymology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects; D016030:Kidney Transplantation; D008297:Male; D020778:Matrix Metalloproteinase 2 / Q000378:metabolism; D008875:Middle Aged
chemical_list: D024042:Collagen Type I; D020536:Enzyme Activators; D007166:Immunosuppressive Agents; D017963:Azithromycin; D016572:Cyclosporine; D020778:Matrix Metalloproteinase 2